Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Nexavar; Belgium: Nexavar; Bulgaria: Nexavar; Czech Republic: Nexavar; Denmark: Nexavar; Estonia: Nexavar; Finland: Nexavar; France: Nexavar; Germany: Nexavar; Greece: Nexavar; Hungary: Nexavar; Ireland: Nexavar; Italy: Nexavar; Latvia: Nexavar; Lithuania: Nexavar; Malta: Nexavar; Netherlands: Nexavar; Poland: Nexavar; Portugal: Nexavar; Romania: Nexavar; Slovakia: Nexavar; Slovenia: Nexavar; Sweden: Nexavar; UK: Nexavar.

North America

Canada: Nevaxar; USA: Nexavar.

Latin America

Argentina: Nexavar; Mexico: Nexavar.


Japan: Nexavar.

Drug combinations


Sorafenib: C~21~H~16~ClF~3~N~4~O~3~. Mw: 464.82. (1) 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; (2) 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide. CAS-284461-73-0 (2006).

Sorafenib Tosylate: C~21~H~16~ClF~3~N~4~O~3~.C~7~H~8~O3S. Mw: 637.00. 1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[4-[[2-(methylcarbamoyl)pyridin-4-yl]oxy]phenyl]urea mono(4-methylbenzenesulfonate). CAS-475207-59-1 (2006).

Pharmacologic Category

Other Antineoplastic Agents; Protein Kinase Inhibitors. Tyrosine Kinase Inhibitor. Vascular Endothelial Growth Factor (VEGF) Inhibitor. (ATC-Code: L01XE05).

Mechanism of action

Multikinase inhibitor. Inhibits tumor growth and angiogenesis by inhibiting intracellular Raf kinases (CRAF, BRAF, and mutant BRAF), and cell surface kinase receptors (VEGFR-2, VEGFR-3, PDGFR-β, cKIT, and FLT-3).

Therapeutic use

Advanced renal cell cancer, unresectable hepatocellular cancer.

Pregnancy and lactiation implications

Teratogenicity and fetal loss shown in animals. There are no adequate studies in humans. As sorafenib inhibits angiogenesis, adverse effects on pregnancy would be expected. Excretion in breast milk unknown (not recommended in nursing women).

Unlabeled use

Advanced thyroid cancer.


Hypersensitivity to sorafenib or any component of the formulation.

Warnings and precautions

Increased risk of bleeding may occur. May cause cardiac ischemia or infarction (use with caution in cardiovascular disease). Hand-foot skin reaction and rash are most common adverse events. GI perforation reported. May cause hypertension, especially in first 6 weeks of treatment (caution if underlying or poorly-controlled hypertension). May complicate wound healing. Avoid concurrent use (if possible) with strong CYP3A4 inducers. Use caution when administering sorafenib with compounds metabolized predominantly via UGT1A1.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart